Relmada Therapeutics (RLMD) Interest Coverage Ratio (2012 - 2015)
Relmada Therapeutics (RLMD) posted quarterly Interest Coverage Ratio of 0.51 for Q1 2026, up 99.87% year-over-year from 0.26 in Q1 2025, and up 99.94% quarter-over-quarter from 807.99 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Interest Coverage Ratio (2012 - 2015) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Interest Coverage Ratio for 15 consecutive years, with 0.51 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 99.87% year-over-year to 0.51; the TTM figure through Mar 2026 stood at 1.59 (up 99.73% YoY), while the FY2025 annual figure was 8.55, up 98.62% from the prior year.
- Interest Coverage Ratio climbed to 0.51 in Q1 2026 per RLMD's latest filing, from 807.99 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.51 in Q1 2026 and bottomed at 1209.51 in Q4 2023.
- Historically, Interest Coverage Ratio has averaged 433.79 across 5 years, with a median of 490.34 in 2023.
- Annual changes were most pronounced in 2025 — Interest Coverage Ratio plunged 25064.83% — and 2026, when it soared 99.87%.
- Relmada Therapeutics' Interest Coverage Ratio stood at 92.59 in 2022, then sank by 1206.31% to 1209.51 in 2023, then surged by 43.67% to 681.32 in 2024, then fell by 18.59% to 807.99 in 2025, then surged by 99.94% to 0.51 in 2026.
- Business Quant data shows RLMD's Interest Coverage Ratio at 0.51 in Q1 2026, 807.99 in Q4 2025, and 381.94 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2015 | -4,882.52 |
| Sep 30, 2015 | -2,819.49 |
| Jun 30, 2015 | -10,215.86 |
| Mar 31, 2015 | -36,626.46 |
| Dec 31, 2014 | -3,993.52 |
| Sep 30, 2014 | -1,139.10 |
| Jun 30, 2014 | -29.72 |
| Mar 31, 2014 | -20.66 |
| Feb 28, 2013 | -5.73 |
| Nov 30, 2012 | -29.19 |
| Aug 31, 2012 | -8.23 |
| May 31, 2012 | -0.96 |